Transforming Psychotherapy for Chronically Ill Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Select one category that most adequately describes your research:
Pilot
Discuss the research design including but not limited to such issues as: probability of group assignment, potential for subject to be randomized to placebo group, use of control subjects, etc.
The proposed project is designed to pilot test the feasibility of a brief psychosocial intervention among depressed and/or anxious medical patients with confirmed symptoms of COPD and/or CHF causing significant impairment as ascertained by validated surveys. We will test the intervention with an open-trial format. Therefore, all patients who meet the inclusion criteria described below will receive the intervention. Group assignment, randomization, and use of control subjects are not applicable to this pilot research project. Data will be collected at baseline, post-treatment (8 weeks), and at 3 month follow-up. Trained members of the study staff will conduct assessments, intervention and follow-up sessions following a protocol. A licensed psychologist will supervise all members of the study staff.
F2. Procedure
Recruitment Procedures: Patients with COPD and CHF who meet criteria for clinically significant physical and emotional symptoms will be recruited. Recruitment of potential participants (detailed further in Section J) will occur through database extractions (e.g. ICD-9 codes), primary care provider referrals, and specialty care provider referrals (e.g. cardiology and pulmonology). Patients will then be contacted via letter, which provides basic information about the study. If no response from the person is received within 5 days, a study research assistant will contact the person via telephone to determine if they are interested and eligible for participation in the study. These procedures are currently being used in related IRB approved studies H#19681 "Mental Health Treatment Engagement In CHF Patients With Depression And Anxiety", and H-19629 "Identifying Mental Health Treatment Barriers in Medically Ill Older Adults".
Telephone Screening: A trained research assistant will administer the 15 minute telephone screen. Prior to the initiation of the telephone screen, patients will be provided with study informed consent and patient verbal assent will be obtained. Following consent, patients will be asked a series of questions to assess: patient information (e.g. demographic data), symptoms of heart failure and/or symptoms of COPD, cognitive functioning (6-item screener), and brief mental health service use history. The RA will also determine eligibility by administering five items from the PRIME-MD to screen for anxiety and depression. Given its high sensitivity to detect depression and anxiety, use of the PRIME-MD will reduce the number of patients without symptoms of depression or anxiety unnecessarily attending in-person interview. If the patient meets study eligibility, they will be invited to attend an in-person study interview.
In-person Screening: Initial screen eligible patients will be invited to an in-person appointment where final eligibility will be determined and baseline assessment measures completed. All appointments will take place at the designated research site. Demographic information will be collected for: age, gender, ethnicity, household income, marital status, education, employment status, and current/past smoking (e.g. pack years). Medical history information will be collected for: date of onset/diagnosis of CHF and/or COPD, current medication usage, and history of other significant illness. The MINI psychiatric interview will be used to determine the presence of DSM-IV Axis I disorders. Symptoms of anxiety and depression will be assessed using self-report and clinician rated instruments to determine final eligibility. Other baseline measures will include assessments for psychiatric diagnoses (semi-structured clinical interview), quality of life (disease specific and general), and health service utilization (by patient self-report). All patients who meet the eligibility requirements described in Section F will be invited to receive the intervention. A study clinician will initiate contact with the patient via telephone and subsequently set up an initial treatment session.
Intervention: The intervention is a psychosocial treatment that was specifically developed to address the mental health and quality of life needs for chronically ill patients. As such the intervention contains a number of unique characteristics that are designed to better address the mental and physical health needs of these patients. It is a skills-based intervention that matches patients' expressed desire for improved quality of life within focused intervention modules based on their symptom profile and preferences for care. Modules are guided by a symptom-based algorithm but ultimately patients choose the intervention focus with the clinician serving as a consultant or guide. All patients receive two core modules focused on increasing awareness and controlling symptoms that emphasizes the overlap and distinction between mental health and physical heath symptoms. At the conclusion of the core modules, patients work with their study clinician to set initial goals for improving quality of life. Goals need not be restricted to "mental health" (e.g. reducing symptoms of depression or anxiety) but can also focus on stress and concerns about their physical condition (e.g. improving functioning and general quality of life by actively coping with a chronic medical illness). Following the core modules, patients are provided with a series of module choices from which they select skills training that matches their current and most pressing needs. Collectively, the active treatment phase is provided over 6 weekly sessions (2 core sessions and 4 elective module sessions). Each session is followed by a brief telephone follow-up that occurs between 1 and 3 days before the next session. At the conclusion of the active treatment phase, the participant will receive three follow-up telephone calls at weeks 8, 10, and 12 (referred to as booster telephone calls) to review skills, encourage continued practice, and facilitate consolidation of treatment gains.
Assessments: Data will be collected at baseline, post-treatment (8 weeks), and at 3-month follow-up.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Houston VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmation of CHF or COPD diagnosis according to medical chart review
- Ongoing symptoms of functional limitations due to CHF (NYHA classification of II , III, or IV as obtained by telephone interview) or COPD (Score of 3 or greater on the Medical Research Council Dyspnoea Scale [MRC] as obtained by telephone interview)
- Eligible patients must have clinically significant symptoms of either anxiety and/or depression as measured using patient self report questionnaires. Clinical cutoff scores for depression will be based on the Beck Depression Inventory - Second Edition (scores of 14 or more) while anxiety cutoffs will be determined using the State-Trait Anxiety Inventory (score of 40 or greater)
- Eligible patients will be English-speaking, as this intervention has not yet been translated to any other language.
Exclusion Criteria:
- History of substance abuse, bipolar disorder, psychosis or active suicidal intent (obtained from chart review and standardized structured clinical interview)
- NYHA class I, or MRC levels 1 and 2. Class 1 CHF patients and Level 1 and 2 COPD patients (by definition) will have no significantly limiting CHF or COPD symptoms. This information will be obtained through patient self-report of CHF and COPD symptoms
- Mental status examination score in the cognitively impaired range on an established 6-item screen
- Inability to provide informed consent or severe physical limitations restricting completion of the study protocol (e.g. vision, hearing, or physical functioning)
- Non-English speaking patients will be excluded from participation, as this intervention has not yet been translated to any other language.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: 1
This study is an open pilot; therefore all participants were given the opportunity to receive treatment.
|
The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression.
Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention.
Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression.
If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
State-trait Anxiety Inventory (STAI), a 40-item self-report measure of anxiety symptoms.Beck Depression Inventory-II (BDI-II), assessing 21 depression symptoms. Client Satisfaction Questionnaire (CSQ), an 8-item, empirical, self-report measure.
Time Frame: Assessments at baseline, post treatment, and 3 month follow-up.
|
Assessments at baseline, post treatment, and 3 month follow-up.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Kansas City Cardiomyopathy Questionnaire (KCCQ), a 23-item self-report measure of constructs. Chronic Respiratory Questionnaire (CRQ), measuring QoL change over time in COPD patients. Short Form 36 (SF-36), a generic measure of health-related QoL.
Time Frame: Assessments at baseline, post treatment, and 3 month follow-up.
|
Assessments at baseline, post treatment, and 3 month follow-up.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jeffrey Cully, PhD MEd BS, Michael E. DeBakey VA Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MIRECC001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
NCT07082998RecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression Disorder
-
NCT05267340Active, not recruitingDepression Moderate | Depression Mild | Depression, Teen
-
NCT04211467WithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression Chronic
-
NCT07617467RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive Disorder
-
NCT04504175CompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant Depression
-
NCT06979544CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal Depression
-
NCT06374056Active, not recruitingDepression | Depression Moderate | Depression Severe | Depression Mild
-
NCT06809907RecruitingDepression | Depression Moderate | Depression Severe | Depression Mild
-
NCT07464886Recruiting
-
NCT07416747Not yet recruitingDepression | Depression in Adults | Depression Disorder
Clinical Trials on ACCES - Adjusting to Chronic Conditions with Education and Support
-
NCT00727155CompletedDepression | Anxiety
-
NCT07214012RecruitingShort Interpregnancy Intervals | Maternal Health Disparities
-
NCT06451003RecruitingCancer | Surgery | Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism
-
NCT00379652CompletedHypertension | Diabetes Mellitis
-
NCT05515991Active, not recruitingEnd-stage Kidney Disease
-
NCT03995043Not yet recruitingPregnancy Related | Contraception | Reproductive Behavior
-
NCT04512924CompletedPsychosocial Problem | Caregiver Burnout | Family Research | Food Allergy in Children
-
NCT05435586CompletedSelf Efficacy | Breast Feeding, Exclusive
-
NCT04870736Withdrawn